Hanoi Medical University
Hanoi, 100000, Vietnam
NCT Number: NCT03460080
The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate the diagnostic efficiency of alpha-fetoprotein-L3 (AFP-L3) and Protein Induced by Vitamin K Absence or antagonist-II (PIVKA-II). This study is performed at Hanoi Medical University Hospital. Participants including patients with HCC and hepatic hemangioma. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II, AFP, AFP-L3 and biochemical indexes including alanine aminotransferase(ALT),aspartate aminotransferase (AST), gamma-glutamyl transferase, HbsAg, Anti HCV, etc.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Observational
Hanoi, 100000, Vietnam
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II), also known as des-γ-carboxyprothrombin (DCP) or acarboxy prothrombin, is an abnormal form of prothrombin induced by vitamin K absence or antagonist-II. The study is intended to evaluate the diagnostic efficiency of AFP-L3 and PIVKA-II. AFP-L3 and PIVKA-II as an effective tumor marker for hepatocellular carcinoma(HCC). Despite the extensive application of PIVKA-II in some hospitals from Vietnam, the diagnostic efficiency including sensitivity, specificity, positive predictive value and negative predictive value still needs more clinical data to evaluate. The research purposes list as follows:1. Determination of changes in AFP-L3 and PIVKA II for HCC.2. Investigating the diagnostic value of AFP-L3 and PIVKA II for HCC. This study is performed at Hanoi Medical University Hospital. Participants including patients with HCC and hepatic hemangioma. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II, AFP, AFP-L3 and biochemical indexes including alanine aminotransferase(ALT),aspartate aminotransferase (AST), gamma-glutamyl transferase, HbsAg, Anti HCV, etc.The diagnosis of HCC was based on HCC criteria of Ministry of Public Health of Vietnam. All HCC diagnoses were confirmed at the time of analysis. Stages of tumor is evaluated by Barcelana classification. The Student's t-test (or Mann-Whitney test) was used to compare continuous variables, and the chi-square test (or Fisher's exact test) was used for categorical variables. A receiver operator characteristic (ROC) curve was used to assess the performance characteristic of PIVKA-II,AFP,AFP-L3 measurement.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.
Imaging: CT or MRI
Time frame: Day one
Using PIVKA-II assay kit (chemiluminescent microparticle immunoassay)
Time frame: Day one
Using chemiluminescent microparticle immunoassay to measure AFP levels
Time frame: Day one
Using µTASWako i30 automated immunoassay analyzer to measure AFP-L3% levels
Time frame: Day one
Using Abbott Architect automated immunoassay analyzer to measure ALT levels
Time frame: Day one
Using Abbott Architect automated immunoassay analyzer to measure AST levels
Time frame: Day one
Using Abbott Architect automated immunoassay analyzer to measure γ-GT levels
Time frame: Day one
Using Abbott Architect automated immuno-analyzer to measure HBsAg levels
Time frame: Day one
Using Abbott Architect automated immunoassay analyzer to measure Anti HCV levels
Time frame: Day one
Using Abbott Architect automated immunoassay analyzer to measure Albumin levels
Time frame: Day one
Using Abbott Architect automated immunoassay analyzer to measure PT (%)
Hanoi Medical University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05858736
Adenocarcinoma, Adnexal Diseases
Darlinghurst, New South Wales, Australia
View Trial DetailsNCT01300143
Adenocarcinoma, Carcinoma
Amiens, France
View Trial DetailsNCT02968810
Adenocarcinoma, Carcinoma
Los Angeles, California, United States
View Trial DetailsNCT03674073
Adenocarcinoma, Carcinoma
Beijing, Beijing Municipality, China
View Trial Details